𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid

✍ Scribed by William K. Oh; Kevin Proctor; Mari Nakabayashi; Carolyn Evan; Lauren K. Tormey; Timothy Daskivich; Lucia Antràs; Michael Smith; Maureen P. Neary; Mei Sheng Duh

Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
124 KB
Volume
109
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The impact of zoledronic acid therapy in
The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis
✍ Kostantinos Zarogoulidis; Eufimia Boutsikou; Pavlos Zarogoulidis; Ellada Elefthe 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 French ⚖ 213 KB 👁 1 views

## Abstract Bone metastases occur in 20–40% of patients with lung cancer. Recent studies demonstrate a direct antiproliferative effect of 3rd generation bisphosphonates (BPs) on lung tumors, which may influence the survival. Therefore, we examined the clinical impact of zoledronic acid (ZOL; Zometa

Zoledronic acid is superior to pamidrona
Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion
✍ Lee S. Rosen; David H. Gordon; William Dugan Jr.; Pierre Major; Peter D. Eisenbe 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB 👁 1 views

## Abstract ## BACKGROUND Treatment with zoledronic acid (Zol) was compared with a dose of 90 mg of pamidronate (Pam) in breast carcinoma (BC) patients with at least 1 osteolytic lesion based on data from a Phase III, randomized trial. ## METHODS Overall, 1130 patients with breast carcinoma who

A Phase II study of estramustine, doceta
A Phase II study of estramustine, docetaxel, and carboplatin with granulocyte–colony-stimulating factor support in patients with hormone-refractory prostate carcinoma : Cancer and Leukemia Group B 99813
✍ William K. Oh; Susan Halabi; W. Kevin Kelly; Cary Werner; Paul A. Godley; Nichol 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB 👁 2 views

## Abstract ## BACKGROUND The authors determined the safety and efficacy of estramustine, docetaxel, and carboplatin with granulocyte–colony‐stimulating factor (G‐CSF) support in patients with hormone‐refractory prostate carcinoma. ## METHODS In the current multicenter, cooperative group study,